Harmony Biosciences (NASDAQ: HRMY) reported Q1 EPS of $1.03, $0.42 better than the analyst estimate of $0.61. Revenue for the quarter came in at $184.7 million versus the consensus estimate of $184.26 million.

GUIDANCE:

Harmony Biosciences sees FY2025 revenue of $820-860 million, versus the consensus of $840.4 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.